The GHK hair-combination trial
A human hair-count result deserves attention. So does the second ingredient in the preparation.
A combination tested in men
The human hair study has the kind of outcome I appreciate: a complex of 5-aminolevulinic acid and GHK increased hair count compared with placebo. The trial involved 45 men with androgenetic alopecia and lasted 6 months. Those details give the finding a population, a period of observation and a material that can actually be named.
At first, GHK monopolised my attention. The combination changed my assessment. The experiment tested both ingredients together, so the favourable result belongs to that preparation. Assigning the result to GHK-Cu alone would erase a component of the experiment. The distinction between GHK and its copper complex adds another reason to retain the paper's actual description.
To my taste, that specificity improves the finding, even if it makes a sweeping headline less convenient. A combination with a measured result is a specific lead for further investigation. There is no need to enlarge it into a finding about every copper-peptide preparation.
Hair count over the trial period
The trial reported a statistically significant hair-count increase versus placebo over 6 months. Counting hairs answers a more definite question than saying that hair looked better. I value that precision. It gives a result something solid to refer to when impressions and expectations begin to crowd around it.
The concentration comparison has a wrinkle of its own. The reported hair-count increases were 71.5 for the 50 mg/mL preparation and 52.6 for the 100 mg/mL preparation, versus 9.6 for placebo. The lower-concentration preparation had the larger reported increase. The concentrations identify the preparations in this trial. I would hesitate to tell a tidy “stronger means better” story from those figures.
The duration belongs to the experiment too. It describes the period over which the participants were observed. Extending that result to an enduring effect after the trial would require observations of what happened afterwards. The name Evertrue makes me particularly demanding on that point: a lasting impression and a lasting measured effect are separate things to establish.
The population also remains specific. This trial involved men with androgenetic alopecia. Other explanations of hair loss, other populations and other preparations remain unexamined by this trial. That restraint preserves a human result that is interesting enough on its own.
AHK-Cu in isolated follicles
A separate laboratory study examined AHK-Cu, a related copper tripeptide. It found elongation of human hair follicles outside the body and proliferation of dermal papilla cells in culture. It also reported reduced apoptosis, the process of cell death, under its experimental conditions. The compound identity matters here: the study used AHK-Cu.
The broad title, “The effect of tripeptide-copper complex on human hair growth in vitro,” makes it easy to lose that identity while remembering the attractive outcome. I set the papers side by side and notice the mismatch immediately. The hair-count trial tested a GHK-containing combination in people; the follicle study tested AHK-Cu in laboratory preparations. Each has its own result.
To my mind, putting these papers together generates a worthwhile research question about related peptides and hair biology. It does not combine them into a trial of pure GHK-Cu in people. A follow-up experiment could isolate each ingredient’s contribution in the GHK combination; that would settle a question the existing mixture leaves open.
Adverse-event record
The combination trial reported no adverse events in any group. That is a welcome observation within this trial. A claim about the safety of another formulation, another population or a longer period would need its own support. The absence of reported harm deserves acknowledgement; an assurance about every use would go well beyond what I can credit to this trial.
The reading list places the combination trial and the AHK-Cu paper beside the skin and delivery research. Their differences become clearer when their titles are allowed to remain specific.